Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 917 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Neoplasm Clear all
Completed Not applicable Interventional

Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears

NCT00483288
View directory record Official record
Conditions
Cervical Cancer
Interventions
educational intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00083213
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears

NCT00084903
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Colposcopic biopsy, Light-Scattering Spectroscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,070 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 7, 2026, 2:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

NCT02355262
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Health Status Unknown, Human Papillomavirus Infection, Malignant Neoplasm
Interventions
Informational Intervention
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 7, 2026, 2:59 PM EDT
Recruiting Not applicable Interventional

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

NCT05197881
View directory record Official record
Conditions
Cervical Cancer by FIGO Stage 2018
Interventions
Varian Ethos Adaptive Radiation Therapy
Device
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
5
States / cities
Burmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 7, 2026, 2:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer

NCT00473798
View directory record Official record
Conditions
Psychosocial, Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2020
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 7, 2026, 2:59 PM EDT
Terminated Not applicable Interventional

Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

NCT01613521
View directory record Official record
Conditions
Cervical Cancer
Interventions
DCE-MRI and 18F-FMISO PET
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 7, 2026, 2:59 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

NCT00193934
View directory record Official record
Conditions
Cancer of the Uterine Cervix
Interventions
Not listed
Lead sponsor
Trans Tasman Radiation Oncology Group
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 7, 2026, 2:59 PM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

NCT00973362
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay, FDA-Approved HPV DNA Test
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
12,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
17
States / cities
Jonesboro, Arkansas • Canoga Park, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 7, 2026, 2:59 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT05799274
View directory record Official record
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
RAD301 ([68Ga]-RAD301)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Princeton, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 7, 2026, 2:59 PM EDT
Terminated Not applicable Interventional

Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue

NCT00250055
View directory record Official record
Conditions
Cervix, Cancer
Interventions
Colposcopy, Spectroscopy, and Biopsy
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 7, 2026, 2:59 PM EDT
Terminated Phase 1 Interventional

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

NCT03277482
View directory record Official record
Conditions
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 7, 2026, 2:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling

NCT07232355
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Not listed
Lead sponsor
Atila Biosystems Inc.
Industry
Eligibility
30 Years to 64 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 7, 2026, 2:59 PM EDT
Terminated No phase listed Observational

Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

NCT00571415
View directory record Official record
Conditions
Cervix Cancer
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Not applicable Interventional

GYNecologic Cancer-Related COGnitive Impairment

NCT06662435
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
Interventions
GYNCOG
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 3 Interventional

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Interventions
Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
Drug · Other
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Not applicable Interventional

CPR Decision Aid For Patients With Advanced Gynecologic Malignancies

NCT03251976
View directory record Official record
Conditions
Advance Care Planning
Interventions
video, usual care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 1 Interventional Results available

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
SL-279252
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 1 Interventional Results available

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

NCT03738228
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8
Interventions
Atezolizumab, Brachytherapy, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 7, 2026, 2:59 PM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 7, 2026, 2:59 PM EDT
Completed Phase 2 Interventional Results available

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT00309959
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Interventions
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
26
States / cities
Aurora, Colorado • Chicago, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 7, 2026, 2:59 PM EDT